
  
    
      
        Background_NNP
        Promoter_NNP methylation_NN has_VBZ been_VBN well_RB recognized_VBN as_IN an_DT
        important_JJ epigenetic_JJ change_NN in_IN the_DT development_NN of_IN cancer_NN [_NN
        1_CD ]_NN ._. Normally_RB ,_, CpG_NNP islands_NNS in_IN the_DT promoter_NN regions_NNS of_IN a_DT
        number_NN of_IN genes_NNS are_VBP present_JJ in_IN an_DT unmethylated_JJ state_NN [_NN 2_CD ]_NN
        ._. Aberrant_NNP methylation_NN of_IN CpG_NNP islands_NNS in_IN promoters_NNS is_VBZ
        characteristic_NN of_IN several_JJ genes_NNS in_IN cancer_NN leading_VBG to_TO loss_NN
        of_IN gene_NN expression_NN ._. A_DT nonrandom_NN pattern_NN of_IN promoter_NN
        hypermethylation_NN has_VBZ been_VBN noted_VBN in_IN specific_JJ genes_NNS in_IN
        specific_JJ tumor_NN types_NNS ,_, although_IN some_DT genes_NNS are_VBP commonly_RB
        methylated_JJ in_IN diverse_JJ tumors_NNS [_NN 3_CD 4_CD ]_NN ._. The_DT extent_NN of_IN
        aberrant_NN promoter_NN hypermethylation_NN and_CC its_PRP$ association_NN with_IN
        loss_NN of_IN gene_NN function_NN in_IN cancer_NN suggests_VBZ that_IN CpG_NNP island_NN
        methylation_NN is_VBZ an_DT important_JJ mechanism_NN in_IN inactivating_VBG tumor_NN
        suppressor_NN genes_NNS (_( TSGs_NNP )_) ._.
        Germ_NNP cell_NN tumors_NNS (_( GCTs_NNP )_) are_VBP the_DT most_RBS common_JJ cancer_NN in_IN
        men_NNS between_IN the_DT ages_NNS 20_CD -_: 40_CD with_IN an_DT incidence_NN of_IN 4_CD ._. 2_CD cases_NNS
        per_IN 100_CD ,_, 000_CD [_NN 5_CD ]_NN ._. GCTs_NNP arise_VB by_IN transformation_NN of_IN
        spermatogonial_NN lineage_NN cells_NNS and_CC display_NN pluripotentiality_NN
        for_IN embryonal_NN and_CC extra-embryonal_JJ lineage_NN differentiation_NN [_NN
        6_CD ]_NN ._. Histologically_NNP ,_, they_PRP may_MD present_VBP as_IN undifferentiated_JJ
        germ_NN cell_NN (_( GC_NNP )_) -_: like_IN seminomas_NNS (_( SGCTs_NNP )_) or_CC highly_RB
        differentiated_JJ nonseminomas_NNS (_( NSGCTs_NNP )_) ._. NSGCTs_NNP display_NN
        complex_JJ differentiation_NN patterns_NNS that_WDT include_VBP embryonal_NN ,_,
        extra-embryonal_JJ ,_, and_CC somatic_JJ tissue_NN types_NNS [_NN 6_CD ]_NN ._. Teratomas_NNP
        with_IN somatic_JJ differentiation_NN can_MD undergo_VB additional_JJ
        malignant_JJ transformation_NN with_IN characteristics_NNS of_IN
        epithelial_NN ,_, mesenchymal_NN ,_, neurogenic_JJ ,_, or_CC hematologic_JJ tumors_NNS
        [_NN 7_CD ]_NN ._. While_IN the_DT majority_NN of_IN GCTs_NNP exhibit_NN exquisite_JJ
        sensitivity_NN to_TO cisplatin-based_JJ chemotherapy_NN ,_, a_DT small_JJ
        proportion_NN of_IN metastatic_JJ tumors_NNS remain_VBP resistant_JJ ._.
        Therefore_RB ,_, male_JJ GCTs_NNP comprise_VBP a_DT unique_JJ model_NN system_NN to_TO
        investigate_VB the_DT biology_NN and_CC genetics_NNS of_IN GC_NNP transformation_NN ,_,
        differentiation_NN ,_, and_CC chemotherapy_NN resistance_NN /_NN sensitivity_NN [_NN
        6_CD ]_NN ._.
        During_IN the_DT life_NN span_NN of_IN a_DT normal_JJ GC_NNP ,_, extensive_JJ
        methylation_NN reprogramming_VBG occurs_VBZ [_NN 6_CD ]_NN ._. However_RB ,_, the_DT role_NN
        of_IN epigenetic_JJ changes_NNS in_IN GCT_NNP etiology_NN and_CC biology_NN are_VBP not_RB
        well_RB studied_VBN ._. To_TO investigate_VB such_PDT a_DT role_NN ,_, we_PRP evaluated_VBD the_DT
        status_NN of_IN promoter_NN hypermethylation_NN of_IN 21_CD genes_NNS in_IN GCT_NNP
        specimens_NNS and_CC cell_NN lines_NNS ._. We_PRP found_VBD an_DT absence_NN of_IN promoter_NN
        hypermethylation_NN in_IN SGCT_NNP and_CC acquisition_NN of_IN unique_JJ patterns_NNS
        of_IN promoter_NN hypermethylation_NN in_IN NSGCT_NNP ._. We_PRP also_RB showed_VBD that_IN
        the_DT hypermethylation_NN leads_VBZ to_TO loss_NN of_IN expression_NN in_IN most_JJS of_IN
        the_DT genes_NNS and_CC reactivate_NN upon_IN treatment_NN with_IN demethylating_VBG
        drug_NN 5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN ._.
      
      
        Results_NNS
        
          Promoter_NNP hypermethylation_NN is_VBZ common_JJ in_IN NSGCT_NNP and_CC
          rare_JJ in_IN SGCT_NNP
          We_PRP assessed_VBD 92_CD GCT_NNP DNAs_NNP representing_VBG all_DT histologic_JJ
          subsets_NNS of_IN NSGCT_NNP ,_, and_CC SGCT_NNP ,_, and_CC four_CD normal_JJ testes_NNS for_IN
          methylation_NN status_NN of_IN CpG_NNP islands_NNS of_IN 21_CD gene_NN promoters_NNS by_IN
          methylation-specific_JJ PCR_NNP (_( MSP_NNP )_) (_( Fig_NNP ._. 1_LS )_) ._. Of_IN these_DT ,_, 15_CD
          genes_NNS (_( 
          MGMT_NNP ,_, 
          RASSF_NNP 1_CD A_DT ,_, 
          APC_NNP ,_, 
          RARB_NNP ,_, 
          CDH_NNP 1_CD ,_, 
          MLH_NNP 1_CD ,_, 
          TIMP_NNP 3_CD ,_, 
          GSTP_NNP 1_CD ,_, 
          DAPK_NNP ,_, 
          CDKN_NNP 2_CD A_DT ,_, 
          p_NN 14_CD 
          ARF_NNP ,_, 
          BRCA_NNP 1_CD ,_, 
          FHIT_NNP ,_, 
          TP_NNP 73_CD ,_, and_CC 
          HIC_NNP 1_LS )_) had_VBD previously_RB been_VBN shown_VBN to_TO
          be_VB commonly_RB methylated_JJ in_IN various_JJ solid_JJ tumor_NN types_NNS [_NN 4_CD ]_NN
          ._. Six_CD additional_JJ genes_NNS (_( 
          RB_NNP 1_CD ,_, 
          NME_NNP 1_CD ,_, 
          NME_NNP 2_CD ,_, 
          BTG_NNP 1_CD ,_, 
          NEDD_NNP 1_CD ,_, and_CC 
          APAF_NNP 1_LS )_) were_VBD studied_VBN because_IN of_IN
          their_PRP$ possible_JJ involvement_NN in_IN genetic_JJ alterations_NNS in_IN GCT_NNP
          as_IN indicated_VBN by_IN LOH_NNP studies_NNS [_NN 8_CD 9_CD 10_CD ]_NN ._. The_DT 
          RB_NNP 1_CD gene_NN at_IN 13_CD q_NN 14_CD ._. 2_LS showed_VBD frequent_JJ
          loss_NN of_IN heterozygosity_NN (_( LOH_NNP )_) in_IN GCT_NNP [_NN 9_CD ]_NN ._. The_DT 
          NME_NNP 1_CD and_CC 
          NME_NNP 2_CD genes_NNS mapped_VBN to_TO 17_CD q_NN 21_CD ._. 3_LS also_RB
          were_VBD affected_VBN by_IN LOH_NNP and_CC exhibited_VBN loss_NN of_IN expression_NN in_IN
          teratoma_NN [_NN 9_CD ]_NN ._. The_DT 
          BTG_NNP 1_CD ,_, 
          APAF_NNP 1_CD ,_, and_CC 
          NEDD_NNP 1_CD genes_NNS mapped_VBN to_TO the_DT 12_CD q_NN 22_CD
          common-deletion_JJ region_NN ,_, and_CC thus_RB considered_VBN as_IN candidate_NN
          TSGs_NNP in_IN GCT_NNP [_NN 8_CD 10_CD 11_CD ]_NN ._.
          Promoter_NNP hypermethylation_NN was_VBD not_RB found_VBN in_IN normal_JJ
          testes_NNS for_IN any_DT of_IN the_DT tested_VBN genes_NNS except_IN 
          CDH_NNP 1_CD ._. 
          CDH_NNP 1_CD exhibited_VBN methylation_NN in_IN two_CD
          of_IN the_DT four_CD normal_JJ testes_NNS analyzed_VBD ._. However_RB ,_, promoter_NN
          hypermethylation_NN was_VBD detected_VBN in_IN 43_CD of_IN the_DT 92_CD (_( 46_CD ._. 7_CD %_NN )_)
          GCTs_NNP studied_VBD with_IN an_DT individual_JJ gene_NN frequency_NN of_IN :_: 
          RASSF_NNP 1_CD A_DT ,_, 21_CD ._. 7_CD %_NN ;_: 
          MGMT_NNP ,_, 20_CD ._. 7_CD %_NN ;_: 
          BRCA_NNP 1_CD ,_, 19_CD ._. 8_CD %_NN ,_, 
          HIC_NNP 1_CD ,_, 19_CD ._. 6_CD %_NN ;_: 
          APC_NNP ,_, 9_CD ._. 8_CD %_NN ;_: 
          RARB_NNP ,_, 7_CD ._. 6_CD %_NN ;_: 
          CDH_NNP 1_CD ,_, 7_CD ._. 6_CD %_NN ;_: 
          FHIT_NNP ,_, 6_CD ._. 5_CD %_NN ,_, 
          MLH_NNP 1_CD ,_, 4_CD ._. 3_CD %_NN ;_: 
          TIMP_NNP 3_CD ,_, 3_CD ._. 3_CD %_NN ;_: 
          GSTP_NNP 1_CD ,_, 1_CD ._. 1_CD %_NN ;_: and_CC 
          NME_NNP 2_CD ,_, 1_CD ._. 1_CD %_NN (_( Fig_NNP ._. 1_LS )_) ._. The_DT remaining_VBG
          nine_CD genes_NNS did_VBD not_RB show_VB methylation_NN ._. Hypermethylation_NNP of_IN
          one_CD or_CC more_JJR genes_NNS was_VBD found_VBN only_RB in_IN 5_CD of_IN 29_CD (_( 17_CD ._. 2_LS %_NN )_) SGCTs_NNP
          but_CC in_IN 38_CD of_IN 63_CD (_( 60_CD ._. 3_LS %_NN )_) NSGCTs_NNP (_( Fig_NNP ._. 1_LS )_) ._. Four_CD of_IN the_DT five_CD
          SGCTs_NNP that_WDT exhibited_VBN promoter_NN hypermethylation_NN were_VBD
          methylated_JJ at_IN a_DT single_JJ locus_JJ and_CC one_CD tumor_NN at_IN two_CD loci_NN ,_,
          whereas_IN 27_CD of_IN the_DT 38_CD NSGCTs_NNP exhibited_VBN two_CD or_CC more_RBR
          methylated_JJ loci_NN ._. Promoter_NNP hypermethylation_NN was_VBD seen_VBN in_IN
          all_DT histologic_JJ subsets_NNS of_IN NSGCT_NNP ,_, with_IN yolk_NN sac_NN tumor_NN
          (_( YST_NNP )_) exhibiting_VBG a_DT higher_JJR frequency_NN of_IN methylation_NN
          compared_VBN to_TO other_JJ histologies_NNS (_( Fig_NNP ._. 2_LS &_CC Fig_NNP ._. 3_LS )_) ._.
        
        
          Relationship_NNP between_IN promoter_NN hypermethylation_NN and_CC
          gene_NN expression_NN
          To_TO examine_VB the_DT biological_JJ role_NN of_IN promoter_NN
          hypermethylation_NN in_IN GCT_NNP ,_, we_PRP assessed_VBD the_DT levels_NNS of_IN gene_NN
          expression_NN by_IN semi-quantitative_JJ RT-PCR_NNP in_IN 23_CD tumors_NNS (_( 15_CD
          NSGCTs_NNP and_CC 8_CD SGCTs_NNP )_) with_IN known_VBN methylation_NN status_NN ._. Eight_CD
          genes_NNS (_( 
          MGMT_NNP ,_, 
          RASSF_NNP 1_CD A_DT ,_, 
          BRCA_NNP 1_CD ,_, 
          APC_NNP ,_, 
          RARB_NNP ,_, 
          CDH_NNP 1_CD ,_, 
          MLH_NNP 1_CD ,_, and_CC 
          TIMP_NNP 3_LS )_) that_WDT exhibited_VBN methylation_NN
          in_IN >_NN 3_CD %_NN of_IN the_DT cases_NNS were_VBD examined_VBN (_( Fig_NNP ._. 4_LS ,_, Table_NNP 1_LS )_) ._.
          Levels_NNP of_IN expression_NN of_IN each_DT gene_NN were_VBD assessed_VBN by_IN
          comparing_VBG with_IN the_DT respective_JJ control_NN values_NNS ,_, obtained_VBN
          from_IN the_DT averages_NNS calculated_VBN from_IN 2_CD to_TO 4_CD normal_JJ testes_NNS ,_,
          after_IN normalization_NN against_IN 
          ACTB_NNP ._. All_DT tumors_NNS with_IN promoter_NN
          hypermethylation_NN of_IN the_DT 
          MGMT_NNP and_CC 
          MLH_NNP 1_CD genes_NNS exhibited_VBN an_DT absence_NN or_CC
          down-regulated_JJ expression_NN of_IN the_DT respective_JJ gene_NN ,_, while_IN 8_CD
          of_IN 10_CD cases_NNS with_IN 
          RASSF_NNP 1_CD A_DT methylation_NN and_CC 3_CD of_IN 5_CD
          tumors_NNS with_IN 
          RARB_NNP methylation_NN showed_VBD
          down-regulated_JJ expression_NN (_( Table_NNP 1_LS )_) ._. The_DT other_JJ four_CD genes_NNS
          (_( 
          BRCA_NNP 1_CD ,_, 
          APC_NNP ,_, 
          CDH_NNP 1_CD ,_, and_CC 
          TIMP_NNP 3_LS )_) did_VBD not_RB show_VB a_DT consistent_JJ
          pattern_NN of_IN correlation_NN between_IN methylation_NN and_CC loss_NN of_IN
          gene_NN expression_NN (_( Table_NNP 1_LS )_) ._. Of_IN note_NN ,_, the_DT 
          MGMT_NNP gene_NN exhibited_VBN down-regulated_JJ
          expression_NN in_IN 22_CD of_IN the_DT 23_CD (_( 95_CD ._. 7_CD %_NN )_) tumors_NNS ,_, including_VBG all_PDT
          the_DT tumors_NNS that_WDT showed_VBD promoter_NN methylation_NN ._. No_DT
          consistent_JJ down-regulation_JJ of_IN expression_NN of_IN the_DT other_JJ
          genes_NNS that_WDT lacked_VBD promoter_NN methylation_NN was_VBD detected_VBN in_IN
          the_DT same_JJ panel_NN of_IN specimens_NNS ._. These_DT data_NNS ,_, thus_RB ,_, showed_VBD
          loss_NN of_IN 
          MGMT_NNP expression_NN in_IN majority_NN of_IN GCTs_NNP
          of_IN all_DT histologic_JJ subsets_NNS ._.
        
        
          Demethylation_NNP reactivates_NNS the_DT gene_NN
          expression_NN
          To_TO further_VB examine_VB the_DT role_NN of_IN promoter_NN methylation_NN in_IN
          gene_NN inactivation_NN ,_, we_PRP treated_VBD five_CD NSGCT_NNP cell_NN lines_NNS
          (_( 2102_CD E-R_NNP ,_, 833_CD K-E_NNP ,_, Tera-_NNP 1_CD ,_, Tera-_NNP 2_CD ,_, and_CC 218_CD A_DT )_) with_IN 5_CD -_: Aza-_NNP 2_CD '_POS
          deoxycytidine_NN and_CC analyzed_VBD the_DT expression_NN of_IN 
          MGMT_NNP ,_, 
          RASSF_NNP 1_CD A_DT ,_, 
          RARB_NNP ,_, and_CC 
          BRCA_NNP 1_CD genes_NNS ._. The_DT 
          MGMT_NNP gene_NN exhibited_VBN promoter_NN
          hypermethylation_NN in_IN four_CD of_IN the_DT cell_NN lines_NNS ,_, which_WDT upon_IN
          treatment_NN with_IN 5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN showed_VBD reactivation_NN
          of_IN expression_NN in_IN three_CD (_( 2102_CD E-R_NNP ,_, 833_CD K-E_NNP ,_, and_CC Tera-_NNP 2_LS )_) ._. The_DT
          cell_NN line_NN Tera-_NNP 1_CD did_VBD not_RB reactivate_NN expression_NN after_IN
          azacytidine_NN treatment_NN (_( Fig_NNP ._. 5_LS )_) ._. One_CD cell_NN line_NN (_( T-_NNP 218_CD A_DT )_)
          showed_VBD no_DT promoter_NN hypermethylation_NN of_IN 
          MGMT_NNP by_IN MSP_NNP and_CC no_DT detectable_JJ
          levels_NNS of_IN mRNA_NN expression_NN by_IN RT-PCR_NNP but_CC expression_NN was_VBD
          reactivated_VBN after_IN 5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN treatment_NN ._. Two_CD
          of_IN the_DT five_CD cell_NN lines_NNS showed_VBD methylation_NN in_IN the_DT 
          RARB_NNP gene_NN ,_, one_CD of_IN which_WDT (_( Tera-_NNP 2_LS )_)
          showed_VBD detectable_JJ levels_NNS of_IN gene_NN expression_NN in_IN untreated_JJ
          cells_NNS (_( Fig_NNP ._. 5_LS )_) ._. The_DT other_JJ four_CD cell_NN lines_NNS including_VBG the_DT
          one_CD with_IN promoter_NN hypermethylation_NN (_( 2102_CD E-R_NNP )_) exhibited_VBN no_DT
          detectable_JJ levels_NNS of_IN 
          RARB_NNP expression_NN ._. Azacytidine_NNP
          treatment_NN activated_VBN gene_NN expression_NN in_IN all_PDT the_DT five_CD cell_NN
          lines_NNS ,_, whether_IN or_CC not_RB promoter_NN had_VBD detectable_JJ methylation_NN
          (_( Fig_NNP ._. 5_LS )_) ._. The_DT 
          RASSF_NNP 1_CD A_DT gene_NN was_VBD methylated_JJ in_IN 3_CD of_IN
          the_DT 5_CD cell_NN lines_NNS studied_VBN ._. While_IN one_CD of_IN the_DT methylated_JJ
          cell_NN lines_NNS showed_VBD expression_NN in_IN untreated_JJ cells_NNS ,_, all_DT
          other_JJ cell_NN lines_NNS did_VBD not_RB show_VB detectable_JJ levels_NNS of_IN mRNA_NN ._.
          Azacytidine_NNP treatment_NN reactivated_VBD expression_NN of_IN 
          RASSF_NNP 1_CD A_DT in_IN one_CD of_IN each_DT of_IN the_DT two_CD
          methylated_JJ and_CC two_CD unmethylated_JJ cell_NN lines_NNS ._. The_DT 
          BRCA_NNP 1_CD gene_NN showed_VBD promoter_NN
          methylation_NN in_IN 2_CD of_IN 5_CD cell_NN lines_NNS ._. Irrespective_NNP of_IN whether_IN
          the_DT promoter_NN is_VBZ methylated_JJ or_CC not_RB ,_, the_DT 
          BRCA_NNP 1_CD gene_NN was_VBD expressed_VBN in_IN all_DT
          cell_NN lines_NNS and_CC the_DT treatment_NN of_IN azacytidine_NN had_VBD little_JJ or_CC
          no_DT effect_NN on_IN levels_NNS of_IN gene_NN expression_NN (_( Fig_NNP ._. 5_LS )_)
        
      
      
        Discussion_NNP
        Epigenetic_NNP mechanisms_NNS of_IN gene_NN silencing_VBG are_VBP increasingly_RB
        being_VBG recognized_VBN to_TO affect_VB a_DT number_NN of_IN molecular_JJ pathways_NNS
        in_IN human_JJ cancer_NN [_NN 12_CD ]_NN ._. The_DT extent_NN and_CC the_DT nature_NN of_IN such_JJ
        epigenetic_JJ modifications_NNS in_IN GCTs_NNP are_VBP currently_RB poorly_RB
        understood_VBN ._. Here_RB we_PRP show_VBP that_DT hypermethylation_NN is_VBZ common_JJ in_IN
        NSGCT_NNP and_CC rare_JJ in_IN SGCT_NNP ._. Several_JJ studies_NNS have_VBP shown_VBN that_IN
        both_DT NSGCTs_NNP and_CC SGCTs_NNP exhibit_NN similar_JJ genetic_JJ alterations_NNS ,_,
        including_VBG isochromosome_NN for_IN the_DT short_JJ arm_NN of_IN chromosome_NN 12_CD ,_,
        i_NNP (_( 12_CD p_NN )_) [_NN 6_CD ]_NN ._. Thus_RB epigenetic_JJ alterations_NNS such_JJ as_IN those_DT
        detected_VBN in_IN the_DT current_JJ study_NN is_VBZ one_CD distinct_JJ molecular_JJ
        change_NN that_IN distinguishes_NNS these_DT two_CD histologic_JJ subsets_NNS ._. The_DT
        rare_JJ CpG_NNP hypermethylation_NN seen_VBN in_IN five_CD SGCT_NNP patients_NNS may_MD be_VB
        due_JJ to_TO the_DT existence_NN of_IN a_DT minor_JJ NSGCT_NNP component_NN that_WDT might_MD
        have_VB escaped_VBN the_DT histologic_JJ diagnosis_NN ._. A_DT unique_JJ feature_NN of_IN
        GCTs_NNP is_VBZ their_PRP$ origin_NN from_IN germ_NN cells_NNS at_IN a_DT stage_NN in_IN
        development_NN where_WRB they_PRP undergo_VBP epigenetic_JJ reprogramming_VBG [_NN 6_CD
        13_CD ]_NN ._. The_DT absence_NN of_IN this_DT epigenetic_JJ modification_NN in_IN SGCTs_NNP
        is_VBZ consistent_JJ with_IN their_PRP$ GC-like_NNP nature_NN as_RB previously_RB noted_VBD
        [_NN 6_CD 14_CD ]_NN ._. On_IN the_DT other_JJ hand_NN ,_, the_DT extensive_JJ promoter_NN
        hypermethylation_NN seen_VBN in_IN NSGCTs_NNP suggests_VBZ a_DT mechanistic_JJ role_NN
        in_IN their_PRP$ potential_JJ for_IN embryonal_NN and_CC extra-embryonal_JJ
        lineage_NN differentiation_NN [_NN 6_CD 14_CD ]_NN ._. Establishment_NNP of_IN DNA_NNP
        methylation_NN in_IN the_DT mammalian_JJ genome_NN is_VBZ controlled_VBN by_IN at_IN
        least_JJS three_CD DNA_NNP methyltransferases_NNS (_( DNMTs_NNP )_) ,_, 
        DNMT_NNP 1_CD ,_, 
        DNMT_NNP 3_CD a_DT and_NN 
        DNMT_NNP 3_CD b_SYM [_NN 15_CD ]_NN ._. The_DT role_NN of_IN these_DT
        DNMTs_NNP in_IN differential_NN de_IN novo_NN methylation_NN in_IN SGCT_NNP vs_NNS ._. NSGCT_NNP
        remains_VBZ to_TO be_VB elucidated_JJ ._.
        The_DT overall_JJ higher_JJR frequency_NN of_IN promoter_NN methylation_NN
        seen_VBN in_IN NSGCTs_NNP is_VBZ noticeably_RB evident_JJ in_IN DNA_NNP repair_NN genes_NNS 
        RASSF_NNP 1_CD A_DT ,_, BRCA_NNP 1_CD ,_, and_CC 
        MGMT_NNP ,_, and_CC the_DT hypermethylated_JJ in_IN
        cancer_NN 1_CD (_( 
        HIC_NNP 1_LS )_) gene_NN ,_, which_WDT encodes_NNS a_DT
        transcription_NN factor_NN ._. These_DT genes_NNS map_VBP to_TO sites_NNS already_RB
        known_VBN to_TO be_VB genetically_RB altered_VBN in_IN GCT_NNP specimens_NNS ._. The_DT
        3_CD p_NN 21_CD ._. 3_LS region_NN to_TO which_WDT 
        RASSF_NNP 1_CD A_DT maps_NNS undergoes_NNS deletions_NNS in_IN
        many_JJ solid_JJ tumor_NN types_NNS ,_, including_VBG GCTs_NNP [_NN 9_CD ]_NN ._. 
        RASSF_NNP 1_CD A_DT encodes_NNS a_DT splice_NN variant_NN of_IN
        human_JJ RAS_NNP effector_NN homologue_NN ,_, which_WDT interacts_NNS with_IN the_DT XPA_NNP
        protein_NN and_CC functions_NNS as_IN a_DT negative_JJ regulator_NN of_IN cell_NN
        growth_NN [_NN 16_CD 17_CD ]_NN ._. 
        RASSF_NNP 1_CD A_DT has_VBZ been_VBN shown_VBN to_TO be_VB
        inactivated_JJ by_IN promoter_NN methylation_NN in_IN a_DT variety_NN of_IN tumor_NN
        types_NNS [_NN 16_CD 17_CD 18_CD 19_CD ]_NN ._. The_DT 17_CD q_NN 21_CD and_CC 17_CD p_NN 13_CD regions_NNS ,_, to_TO
        which_WDT 
        BRCA_NNP 1_CD and_CC 
        HIC_NNP 1_CD map_NN ,_, respectively_RB ,_, also_RB have_VBP
        been_VBN characterized_VBN by_IN high_JJ frequency_NN of_IN LOH_NNP in_IN GCT_NNP [_NN 9_CD ]_NN ._.
        The_DT 
        BRCA_NNP 1_CD gene_NN plays_VBZ critical_JJ roles_NNS in_IN
        DNA_NNP repair_NN and_CC recombination_NN ,_, cell_NN cycle_NN checkpoint_NN
        control_NN ,_, and_CC transcription_NN and_CC has_VBZ been_VBN shown_VBN to_TO be_VB
        hypermethylated_JJ in_IN breast-ovarian_JJ cancer_NN [_NN 4_CD ]_NN ._. The_DT 
        HIC_NNP 1_CD gene_NN is_VBZ also_RB often_RB
        hypermethylated_JJ in_IN many_JJ human_JJ cancers_NNS [_NN 20_CD 21_CD 22_CD ]_NN ._. The_DT
        DNA_NNP repair_NN gene_NN 
        MGMT_NNP encodes_NNS O_NNP (_( 6_CD )_) -_: methylguanine-_NN DNA_NNP
        methyltransferase_NN and_CC this_DT enzyme_NN effectively_RB removes_VBZ DNA_NNP
        adducts_NNS formed_VBN by_IN alkylating_VBG agents_NNS [_NN 23_CD ]_NN ._. Epigenetic_NNP
        inactivation_NN of_IN the_DT 
        MGMT_NNP gene_NN was_VBD reported_VBN in_IN a_DT wide_JJ
        variety_NN of_IN cancers_NNS [_NN 24_CD 25_CD ]_NN ._. Also_RB ,_, a_DT low_JJ frequency_NN of_IN
        methylation_NN of_IN the_DT 
        APC_NNP ,_, 
        RARB_NNP ,_, and_CC 
        FHIT_NNP genes_NNS was_VBD detected_VBN in_IN NSGCTs_NNP ._.
        Thus_RB ,_, the_DT frequent_JJ hypermethylation_NN in_IN the_DT 
        MGMT_NNP ,_, BRCA_NNP 1_CD ,_, and_CC 
        RASSF_NNP 1_CD A_DT ,_, and_CC 
        HIC_NNP 1_CD define_VB the_DT methylation_NN profile_NN
        in_IN NSGCT_NNP ._. These_DT data_NNS suggest_VBP that_DT promoter_NN hypermethylation_NN
        leading_VBG to_TO gene_NN silencing_VBG may_MD affect_VB key_JJ pathways_NNS in_IN germ_NN
        cell_NN tumorigenesis_NNS ._.
        Aberrant_NNP promoter_NN methylation_NN changes_NNS that_WDT occur_VBP in_IN
        cancer_NN are_VBP associated_VBN with_IN transcriptional_NN repression_NN and_CC
        loss_NN of_IN function_NN of_IN the_DT gene_NN by_IN interrupting_VBG the_DT binding_JJ of_IN
        proteins_NNS involved_VBN in_IN transcription_NN activator_NN complex_JJ [_NN 12_CD ]_NN
        ._. Our_PRP$ gene_NN expression_NN analysis_NN by_IN RT-PCR_NNP demonstrated_VBD that_IN
        all_DT tumors_NNS that_WDT showed_VBD methylation_NN of_IN 
        MGMT_NNP and_CC 
        MLH_NNP 1_CD also_RB showed_VBD down-regulated_JJ
        expression_NN ,_, while_IN 
        RASSF_NNP 1_CD A_DT and_CC 
        RARB_NNP genes_NNS showed_VBD down-regulation_JJ of_IN
        mRNA_NN levels_NNS in_IN most_JJS of_IN the_DT methylated_JJ tumors_NNS ._. Thus_RB in_IN these_DT
        cases_NNS ,_, promoter_NN hypermethylation_NN is_VBZ one_CD mechanism_NN whereby_WRB
        gene_NN expression_NN can_MD be_VB deregulated_VBN in_IN GCTs_NNP ._. On_IN the_DT other_JJ
        hand_NN ,_, methylation_NN of_IN 
        BRCA_NNP 1_CD ,_, 
        APC_NNP ,_, 
        CDH_NNP 1_CD ,_, and_CC 
        TIMP_NNP 3_CD genes_NNS did_VBD not_RB correlate_VBP with_IN
        expression_NN levels_NNS ._. Interestingly_RB ,_, 
        MGMT_NNP gene_NN was_VBD also_RB down_RB regulated_VBN in_IN
        14_CD of_IN the_DT 15_CD tumors_NNS that_WDT did_VBD not_RB exhibit_VB methylation_NN by_IN MSP_NNP
        analysis_NN ._. Therefore_RB ,_, these_DT data_NNS indicate_VBP that_IN other_JJ
        epigenetic_JJ and_CC /_NN or_CC genetic_JJ changes_NNS may_MD be_VB involved_VBN in_IN
        regulating_VBG the_DT expression_NN of_IN 
        MGMT_NNP in_IN GCT_NNP ._. The_DT MSP_NNP method_NN detects_NNS
        only_RB methylation_NN of_IN full-length_JJ CpG_NNP islands_NNS and_CC cannot_NN
        identify_VB partial_JJ methylation_NN of_IN the_DT promoters_NNS ._. Thus_RB ,_, role_NN
        of_IN partial_JJ methylation_NN in_IN down-regulating_JJ 
        MGMT_NNP cannot_NN be_VB ruled_VBN out_RP ._. Other_JJ
        epigenetic_JJ mechanisms_NNS involving_VBG defects_NNS in_IN chromatin_NN
        modification_NN factors_NNS such_JJ as_IN the_DT association_NN of_IN methyl-_NN CpG_NNP
        binding_JJ proteins_NNS ,_, acetylation_NN and_CC methylation_NN of_IN histone_NN
        proteins_NNS are_VBP also_RB becoming_VBG known_VBN [_NN 15_CD ]_NN ._. The_DT role_NN of_IN these_DT
        chromatin-mediated_JJ components_NNS in_IN inactivating_VBG the_DT 
        MGMT_NNP gene_NN remains_VBZ to_TO be_VB examined_VBN in_IN
        GCT_NNP ._. To_TO determine_VB whether_IN the_DT down-regulated_JJ expression_NN of_IN
        the_DT 
        MGMT_NNP gene_NN is_VBZ due_JJ to_TO genetic_JJ
        mutations_NNS ,_, we_PRP examined_VBD the_DT entire_JJ coding_VBG region_NN in_IN 30_CD GCTs_NNP
        and_CC found_VBD no_DT inactivating_VBG mutations_NNS (_( unpublished_JJ
        observations_NNS )_) ._.
        Epigenetic_NNP gene_NN silencing_VBG of_IN the_DT 
        MGMT_NNP confers_VBZ enhanced_JJ sensitivity_NN to_TO
        alkylating_VBG agents_NNS in_IN cancer_NN [_NN 24_CD 25_CD ]_NN ._. Lack_NN of_IN
        methylation_NN ,_, on_IN the_DT other_JJ hand_NN ,_, associates_NNS with_IN high-risk_JJ
        of_IN death_NN [_NN 25_CD 26_CD ]_NN ._. It_PRP has_VBZ been_VBN suggested_VBN that_IN the_DT
        high-levels_JJ of_IN 
        MGMT_NNP proteins_NNS contribute_VBP to_TO a_DT
        drug-resistant_JJ phenotype_NN [_NN 27_CD ]_NN ._. More_JJR than_IN 90_CD %_NN of_IN newly_RB
        diagnosed_VBN GCTs_NNP and_CC 70_CD -_: 80_CD %_NN of_IN patients_NNS who_WP present_JJ
        metastatic_JJ disease_NN are_VBP cured_VBN with_IN cisplatin-based_JJ
        chemotherapy_NN [_NN 28_CD ]_NN ._. However_RB ,_, 20_CD -_: 30_CD %_NN of_IN the_DT patients_NNS with_IN
        metastatic_JJ disease_NN exhibit_NN resistance_NN to_TO the_DT cisplatin_NN
        curative_JJ regimen_NN leading_VBG to_TO high_JJ mortality_NN in_IN this_DT group_NN ._.
        The_DT molecular_JJ basis_NN of_IN this_DT exquisite_JJ chemotherapy_NN
        sensitivity_NN of_IN GCT_NNP and_CC resistance_NN is_VBZ poorly_RB understood_VBN ._. We_PRP
        have_VBP previously_RB shown_VBN that_IN subsets_NNS of_IN resistant_JJ tumors_NNS
        exhibit_NN 
        TP_NNP 53_CD gene_NN mutations_NNS and_CC chromosomal_NN
        amplifications_NNS [_NN 6_CD ]_NN ._. However_RB ,_, the_DT role_NN of_IN 
        MGMT_NNP in_IN GCT_NNP sensitivity_NN or_CC resistance_NN
        to_TO chemotherapy_NN is_VBZ not_RB known_VBN ._. Our_PRP$ current_JJ observation_NN that_IN
        undetectable_JJ levels_NNS of_IN 
        MGMT_NNP gene_NN expression_NN in_IN >_NN 95_CD %_NN of_IN
        GCTs_NNP appears_VBZ to_TO suggest_VB that_IN the_DT lack_NN of_IN the_DT
        O_NNP (_( 6_CD )_) -_: methylguanine-_NN DNA_NNP methyltransferase_NN enzyme_NN may_MD direct_VB
        cells_NNS to_TO undergo_VB apoptosis_NNS due_JJ to_TO failure_NN of_IN repair_NN of_IN DNA_NNP
        adducts_NNS formed_VBN by_IN alkylating_VBG agents_NNS ._. Lack_NN of_IN 
        MGMT_NNP expression_NN in_IN the_DT majority_NN of_IN
        GCTs_NNP suggests_VBZ a_DT potential_JJ role_NN for_IN this_DT protein_NN in_IN lack_NN of_IN
        repair_NN of_IN cisplatin-induced_JJ DNA_NNP damage_NN that_WDT may_MD result_VB in_IN
        exquisite_JJ sensitivity_NN in_IN this_DT tumor_NN ._. It_PRP has_VBZ been_VBN shown_VBN that_WDT
        engineered_VBN over-expression_JJ of_IN wild-type_JJ p_NN 53_CD 
        in_IN vitro_NN causes_NNS inhibition_NN of_IN 
        MGMT_NNP transcription_NN in_IN human_JJ tumor_NN
        cells_NNS [_NN 29_CD ]_NN ._. Abundant_NNP over-expression_JJ of_IN wild-type_JJ p_NN 53_CD ,_,
        owing_VBG to_TO their_PRP$ stage_NN of_IN origin_NN ,_, is_VBZ a_DT characteristic_JJ feature_NN
        of_IN GCTs_NNP [_NN 30_CD ]_NN ._. A_DT possibility_NN also_RB exists_VBZ that_IN the_DT 
        MGMT_NNP expression_NN may_MD ,_, in_IN general_JJ ,_, be_VB
        down_RB regulated_VBN in_IN tumors_NNS arising_VBG from_IN embryonic-type_JJ cells_NNS ._.
        To_TO examine_VB this_DT ,_, we_PRP analyzed_VBD 22_CD cases_NNS of_IN Wilms_NNP '_POS tumor_NN but_CC
        found_VBD no_DT decreased_VBD levels_NNS of_IN the_DT 
        MGMT_NNP gene_NN expression_NN (_( data_NNS not_RB
        shown_VBN )_) ._. These_DT data_NNS ,_, therefore_RB ,_, rule_NN out_RP the_DT possibility_NN
        that_IN not_RB all_DT tumors_NNS arising_VBG from_IN embryonic-type_JJ cells_NNS show_VBP
        down-regulated_JJ expression_NN of_IN 
        MGMT_NNP ._.
        Transcriptional_NNP silencing_VBG of_IN genes_NNS resulting_VBG from_IN DNA_NNP
        hypermethylation_NN of_IN CpG_NNP islands_NNS is_VBZ reversed_VBN by_IN treatment_NN of_IN
        the_DT hypo-methylating_JJ agent_NN 5_CD -_: aza-_NN 2_CD '_POS -_: deoxycytidine_NN in_IN a_DT dose_NN
        and_CC duration-dependent_JJ manner_NN ._. Since_IN a_DT number_NN of_IN gene_NN
        promoters_NNS were_VBD hypermethylated_JJ and_CC showed_VBD down-regulated_JJ
        mRNA_NN in_IN GCT_NNP ,_, we_PRP wanted_VBD to_TO test_VB whether_IN hypomethylation_NN
        reactivates_NNS the_DT gene_NN expression_NN in_IN these_DT tumors_NNS ._. We_PRP found_VBD
        that_DT azacytidine_NN treatment_NN resulted_VBD in_IN reactivation_NN of_IN gene_NN
        expression_NN in_IN almost_RB all_DT cell_NN lines_NNS that_WDT showed_VBD promoter_NN
        methylation_NN of_IN 
        MGMT_NNP ,_, RASSF_NNP 1_CD A_DT and_CC 
        RARB_NNP genes_NNS ,_, with_IN the_DT exception_NN of_IN the_DT
        cell_NN line_NN Tera-_NNP 1_CD ._. In_IN addition_NN ,_, a_DT number_NN of_IN genes_NNS that_WDT
        showed_VBD no_DT evidence_NN of_IN full-length_JJ CpG_NNP methylation_NN was_VBD also_RB
        reactivated_VBN upon_IN azacytidine_NN treatment_NN ._. This_DT was_VBD most_RBS
        evident_JJ for_IN the_DT 
        RARB_NNP gene_NN ,_, where_WRB all_DT five_CD cell_NN lines_NNS
        showed_VBD reactivation_NN whether_IN or_CC not_RB the_DT promoter_NN was_VBD
        methylated_JJ ._. These_DT data_NNS thus_RB suggest_VBP that_IN global_JJ
        demethylation_NN may_MD not_RB only_RB influence_VB the_DT expression_NN of_IN
        methylated_JJ genes_NNS but_CC also_RB unmethylated_JJ genes_NNS ._. Such_JJ a_DT
        phenomenon_NN has_VBZ previously_RB been_VBN reported_VBN [_NN 31_CD 32_CD ]_NN ._.
      
      
        Conclusions_NNP
        The_DT data_NNS presented_VBN here_RB show_NN that_DT promoter_NN
        hypermethylation_NN is_VBZ an_DT important_JJ molecular_JJ signature_NN
        differentiating_VBG seminomatous_JJ and_CC nonseminomatous_JJ GCTs_NNP ._.
        Promoter_NNP methylation_NN was_VBD frequently_RB seen_VBN in_IN DNA_NNP repair_NN
        genes_NNS 
        MGMT_NNP ,_, 
        RASSF_NNP 1_CD A_DT ,_, and_CC 
        BRCA_NNP 1_CD ,_, and_CC a_DT transcriptional_NN
        repressor_NN gene_NN 
        HIC_NNP 1_CD ._. Promoter_NNP methylation_NN of_IN most_JJS
        genes_NNS resulted_VBD in_IN transcriptional_NN repression_NN ._. The_DT data_NNS also_RB
        suggest_VBP that_IN multiple_JJ mechanisms_NNS ,_, in_IN addition_NN to_TO the_DT
        promoter_NN methylation_NN ,_, may_MD play_VB a_DT role_NN in_IN silencing_VBG of_IN 
        MGMT_NNP gene_NN expression_NN in_IN GCTs_NNP of_IN all_DT
        histologic_JJ subsets_NNS ._. Given_VBN the_DT importance_NN of_IN the_DT MGMT_NNP
        protein_NN in_IN treatment_NN response_NN to_TO alkylating_VBG agents_NNS ,_, this_DT
        molecular_JJ switch_NN may_MD play_VB a_DT critical_JJ role_NN in_IN sensitivity_NN to_TO
        cisplatin-based_JJ therapy_NN in_IN GCTs_NNP ._. Demethylation_NNP of_IN the_DT
        promoters_NNS reactivated_VBD the_DT gene_NN expression_NN in_IN 
        MGMT_NNP ,_, 
        RARB_NNP and_CC 
        RASSF_NNP 1_CD A_DT genes_NNS ._. Further_RB
        characterization_NN of_IN the_DT exact_JJ mechanisms_NNS involved_VBN in_IN
        epigenetic_JJ gene_NN silencing_VBG ,_, especially_RB in_IN the_DT 
        MGMT_NNP gene_NN ,_, may_MD provide_VB important_JJ
        clues_NNS in_IN understanding_VBG the_DT pathways_NNS relevant_JJ to_TO GCT_NNP
        biology_NN ._.
      
      
        Methods_NNP
        
          Tumor_NNP tissues_NNS and_CC cell_NN lines_NNS
          A_DT total_NN of_IN 92_CD GCT_NNP tumor_NN tissues_NNS consisting_VBG of_IN 83_CD
          primary_JJ tumors_NNS and_CC nine_CD cell_NN lines_NNS were_VBD used_VBN in_IN this_DT
          study_NN ._. The_DT tumor_NN biopsies_NNS were_VBD ascertained_JJ from_IN patients_NNS
          evaluated_VBN at_IN Memorial_NNP Sloan-_NNP Kettering_NNP Cancer_NNP Center_NNP
          (_( MSKCC_NNP )_) as_IN described_VBN previously_RB [_NN 11_CD ]_NN after_IN appropriate_JJ
          institutional_JJ review_NN board_NN approval_NN ._. Frozen_NNP tumor_NN tissues_NNS
          or_CC cell_NN pellets_NNS were_VBD utilized_JJ for_IN DNA_NNP and_CC /_NN or_CC RNA_NNP
          isolation_NN by_IN standard_JJ methods_NNS ._. Histologically_NNP ,_, 29_CD of_IN
          these_DT tumors_NNS were_VBD SGCTs_NNP ,_, 44_CD NSGCTs_NNP ,_, and_CC 19_CD mixed_JJ or_CC
          combined_VBN tumors_NNS ._. Nine_CD cell_NN lines_NNS derived_VBN from_IN GCT_NNP have_VBP
          been_VBN previously_RB described_VBN [_NN 8_CD ]_NN ._. DNA_NNP and_CC RNA_NNP isolated_VBD
          from_IN four_CD normal_JJ testes_NNS were_VBD used_VBN as_IN controls_NNS ._.
        
        
          Methylation_NNP Specific_JJ PCR_NNP (_( MSP_NNP )_)
          Genomic_NNP DNA_NNP was_VBD treated_VBN with_IN sodium_NN bisulphite_NN as_RB
          previously_RB described_VBD [_NN 33_CD ]_NN ._. Placental_NNP DNA_NNP treated_VBD in_IN
          vitro_NN with_IN 
          Sss_NNP I_PRP methyltransferase_NN (_( New_NNP
          England_NNP Biolabs_NNP ,_, Beverly_NNP ,_, MA_NNP )_) and_CC similarly_RB treated_VBN
          normal_JJ lymphocyte_NN DNA_NNP were_VBD used_VBN as_IN controls_NNS for_IN
          methylated_JJ and_CC unmethylated_JJ templates_NNS ,_, respectively_RB ._. The_DT
          primers_NNS used_VBN for_IN methylated_JJ and_CC unmethylated-specific_JJ PCR_NNP
          for_IN genes_NNS 
          RARB_NNP ,_, 
          TIMP_NNP 3_CD ,_, 
          CDKN_NNP 2_CD A_DT ,_, 
          p_NN 14_CD 
          ARF_NNP ,_, 
          MGMT_NNP ,_, 
          DAPK_NNP ,_, 
          CDH_NNP 1_CD ,_, 
          GSTP_NNP 1_CD ,_, 
          APC_NNP promoter_NN 1_CD A_DT ,_, 
          RB_NNP 1_CD ,_, 
          MLH_NNP 1_CD ,_, 
          TP_NNP 73_CD ,_, 
          BRCA_NNP 1_CD ,_, 
          FHIT_NNP ,_, and_CC 
          HIC_NNP 1_CD have_VBP been_VBN described_VBN previously_RB
          http_NN :_: /_NN /_NN pathology_NN 2_CD ._. jhu_NN ._. edu_NN /_NN pancreas_NN /_NN prim_JJ 0425_CD ._. htm_NN #_# MSP_NNP ;_: [_NN 34_CD
          35_CD 36_CD 37_CD ]_NN ._. For_IN additional_JJ genes_NNS ,_, we_PRP designed_VBD the_DT
          following_VBG gene-specific_JJ primers_NNS for_IN methylated_JJ (_( MF_NNP and_CC
          MR_NNP )_) and_CC unmethylated_JJ (_( UF_NNP and_CC UR_NNP )_) sequences_NNS according_VBG to_TO
          Herman_NNP et_CC al_NN [_NN 33_CD ]_NN :_:
          
          BTG_NNP 1_CD -_: MF_NNP
          5_CD '_POS -_: GTCGTTCGTTTTTTACGTTTTT-_NNP 3_CD '_''
          
          BTG_NNP 1_CD -_: MR_NNP
          5_CD '_POS -_: CGACCCGAATATAAAAAAAATAC-_NNP 3_CD '_''
          
          BTG_NNP 1_CD -_: UF_NNP
          5_CD '_POS -_: GTTGTTTGTTTTTTATGTTTTTTTT-_NNP 3_CD '_''
          
          BTG_NNP 1_CD -_: UR_NNP
          5_CD '_POS -_: CAACCCAAATATAAAAAAAATACA-_NNP 3_CD '_''
          
          NEDD_NNP 1_CD -_: MF_NNP
          5_CD '_POS -_: GGATATTTTTTAGTTTAGCGCG-_NNP 3_CD '_''
          
          NEDD_NNP 1_CD -_: MR_NNP
          5_CD '_POS -_: CGACCCCCTATTATATTACTACG-_NNP 3_CD '_''
          
          NEDD_NNP 1_CD -_: UF_NNP
          5_CD '_POS -_: TGGATATTTTTTAGTTTAGTGTG-_NNP 3_CD '_''
          
          NEDD_NNP 1_CD -_: UR_NNP
          5_CD '_POS -_: CAACCCCCTATTATATTACTACA-_NNP 3_CD '_''
          
          APAF_NNP 1_CD -_: MF_NNP
          5_CD '_POS -_: GCGCGTTCGTTTATGTAAATA-_NNP 3_CD '_''
          
          APAF_NNP 1_CD -_: MR_NNP
          5_CD '_POS -_: CAAACCGACGAAACCCGAA-_NNP 3_CD '_''
          
          APAF_NNP 1_CD -_: UF_NNP
          5_CD '_POS -_: GGTGTGTGTTTGTTTATGTAAATA-_NNP 3_CD '_''
          
          APAF_NNP 1_CD -_: UR_NNP
          5_CD '_POS -_: CACAAACCAACAAAACCCAAA-_NNP 3_CD '_''
          
          NME_NNP 1_CD -_: MF_NNP
          5_CD '_POS -_: GTTTCGTGCGTGTAAGTGTTG-_NNP 3_CD '_''
          
          NME_NNP 1_CD -_: MR_NNP
          5_CD '_POS -_: CCACCGACAAAAACGAATCCA-_NNP 3_CD '_''
          
          NME_NNP 1_CD -_: UF_NNP
          5_CD '_POS -_: GTTTTGTGTGTGTAAGTGTTGT-_NNP 3_CD '_''
          
          NME_NNP 1_CD -_: UR_NNP
          5_CD '_POS -_: CCACCAACAAAAACAAATCCAC-_NNP 3_CD '_''
          
          NME_NNP 2_CD -_: MF_NNP
          5_CD '_POS -_: TTTTCGGTCGCGTCGGGTC-_NNP 3_CD '_''
          
          NME_NNP 2_CD -_: MR_NNP
          5_CD '_POS -_: GCGCGAAACCTACGAAAAATC-_NNP 3_CD '_''
          
          NME_NNP 2_CD -_: UF_NNP
          5_CD '_POS -_: GTTTTTTGGTTGTGTTGGGTTG-_NNP 3_CD '_''
          
          NME_NNP 2_CD -_: UR_NNP
          5_CD '_POS -_: CACACAAAACCTACAAAAAATCA-_NNP 3_CD '_''
          
          RASSF_NNP 1_CD A_DT -_: MF_NNP
          5_CD '_POS -_: ACGCGTTGCGTATCGCGCG-_NNP 3_CD '_''
          
          RASSF_NNP 1_CD A_DT -_: MR_NNP
          5_CD '_POS -_: CCGCGACGACTACGCTACC-_NNP 3_CD '_''
          
          RASSF_NNP 1_CD A_DT -_: UF_NNP
          5_CD '_POS -_: ATGTGTTGTGTATTGTGTGGGG-_NNP 3_CD '_''
          
          RASSF_NNP 1_CD A_DT -_: UR_NNP
          5_CD '_POS -_: CCACAACAACTACACTACCCC-_NNP 3_CD '_''
          PCR_NNP products_NNS were_VBD run_VBN on_IN 2_CD %_NN agarose_NN gels_NNS and_CC
          visualized_JJ after_IN ethidium_NN bromide_NN staining_VBG ._. Purified_NNP MSP_NNP
          products_NNS were_VBD sequenced_JJ in_IN representative_NN specimens_NNS by_IN
          direct_JJ sequencing_VBG to_TO confirm_VB the_DT methylation_NN scored_VBD on_IN
          agarose_NN gels_NNS ._.
        
        
          Semi-quantitative_NNP analysis_NN of_IN mRNA_NN
          expression_NN
          To_TO assess_VB gene_NN expression_NN ,_, total_JJ RNA_NNP isolated_VBD from_IN
          normal_JJ testes_NNS ,_, the_DT cell_NN lines_NNS ,_, and_CC tumor_NN tissues_NNS ,_, and_CC
          polyA_NN +_NN RNA_NNP of_IN testis_NNS obtained_VBN from_IN Clontech_NNP (_( Palo_NNP Alto_NNP ,_,
          CA_NNP )_) was_VBD reverse_VB transcribed_JJ using_VBG random_JJ primers_NNS and_CC the_DT
          Pro-_NNP STAR_NNP first_JJ strand_NN RT-PCR_NNP kit_NN (_( Stratagene_NNP ,_, La_NNP Jolla_NNP ,_,
          CA_NNP )_) ._. A_DT semi-quantitative_JJ analysis_NN of_IN gene_NN expression_NN was_VBD
          performed_VBN using_VBG 26_CD to_TO 28_CD cycles_NNS of_IN multiplex_NN RT-PCR_NNP with_IN
          β-actin_JJ (_( 
          ACTB_NNP )_) as_IN control_NN and_CC gene_NN specific_JJ
          primers_NNS spanning_VBG at_IN least_JJS 2_CD exons_NNS ,_, except_IN in_IN 
          RASSF_NNP 1_CD A_DT ._. For_IN the_DT latter_NN ,_, we_PRP used_VBD
          single_JJ PCR_NNP with_IN primers_NNS and_CC conditions_NNS as_RB previously_RB
          described_VBD [_NN 16_CD ]_NN ._. The_DT gene_NN primers_NNS used_VBN and_CC their_PRP$
          positions_NNS in_IN respective_JJ cDNAs_NNS were_VBD :_:
          
          MGMT_NNP -_: F_NN 5_CD '_POS -_: GCACGAAATAAAGCTCCTGG-_NNP 3_CD '_POS
          (_( 124_CD -_: 143_CD bp_NN )_)
          
          MGMT_NNP -_: R_NN 5_CD '_POS -_: AGGGCTGCTAATTGCTGGTA-_NNP 3_CD '_POS
          (_( 380_CD -_: 399_CD bp_NN )_)
          
          MLH_NNP 1_CD -_: F_NN 5_CD '_POS -_: CTGGACGAGACAGTGGTGAA-_NNP 3_CD '_POS
          (_( 52_CD -_: 71_CD bp_NN )_)
          
          MLH_NNP 1_CD -_: R_NN 5_CD '_POS -_: CTCACCTCGAAAGCCATAGG-_NNP 3_CD '_POS
          (_( 308_CD -_: 327_CD bp_NN )_)
          
          APC_NNP -_: F_NN 5_CD '_POS -_: AAGCCGGGAAGGATCTGTAT-_NNP 3_CD '_POS
          (_( 329_CD -_: 348_CD bp_NN )_)
          
          APC_NNP -_: R_NN 5_CD '_POS -_: TCCAATTGCCTTCTGGTCAT-_NNP 3_CD '_POS
          (_( 588_CD -_: 607_CD bp_NN )_)
          
          RARB_NNP -_: F_NN 5_CD '_POS -_: AATTCAGTGAACTGGCCACC-_NNP 3_CD '_POS
          (_( 770_CD -_: 789_CD bp_NN )_)
          
          RARB_NNP -_: R_NN 5_CD '_POS -_: GGCAAAGGTGAACACAAGGT-_NNP 3_CD '_POS
          (_( 1010_CD -_: 1029_CD bp_NN )_)
          
          CDH_NNP 1_CD -_: F_NN 5_CD '_POS -_: CTCGACACCCGATTCAAAGT-_NNP 3_CD '_POS
          (_( 335_CD -_: 354_CD bp_NN )_)
          
          CDH_NNP 1_CD -_: R_NN 5_CD '_POS -_: TGGGCCTTTTTCATTTTCTG-_NNP 3_CD '_POS
          (_( 615_CD -_: 634_CD bp_NN )_)
          
          TIMP_NNP 3_CD -_: F_NN 5_CD '_POS -_: CTTCCGAGAGTCTCTGTGGC-_NNP 3_CD '_POS
          (_( 1440_CD -_: 1450_CD bp_NN )_)
          
          TIMP_NNP 3_CD -_: R_NN 5_CD '_POS -_: GGCGTAGTGTTTGGACTGGT-_NNP 3_CD '_POS
          (_( 1713_CD -_: 1732_CD bp_NN )_)
          
          BRCA_NNP 1_CD -_: F_NN 5_CD '_POS -_: TCAGCTTGACACAGGTTTGG-_NNP 3_CD '_POS
          (_( 676_CD -_: 695_CD bp_NN )_)
          
          BRCA_NNP 1_CD -_: R_NN 5_CD '_POS -_: GGTTGTATCCGCTGCTTTGT-_NNP 3_CD '_POS
          (_( 896_CD -_: 915_CD bp_NN )_)
          The_DT PCR_NNP products_NNS were_VBD run_VBN on_IN 1_CD ._. 5_CD %_NN agarose_NN gels_NNS ,_,
          visualized_JJ by_IN ethidium_NN bromide_NN staining_VBG and_CC quantitated_JJ
          using_VBG the_DT Kodak_NNP Digital_NNP Image_NN Analysis_NNP System_NNP (_( Kodak_NNP ,_, New_NNP
          Haven_NNP ,_, CT_NNP )_) ._. A_DT tumor_NN was_VBD considered_VBN to_TO have_VB lost_VBN
          expression_NN when_WRB the_DT gene_NN showed_VBD complete_JJ lack_NN of_IN
          expression_NN or_CC at_IN least_JJS 50_CD %_NN reduction_NN from_IN the_DT normalized_JJ
          values_NNS obtained_VBN from_IN the_DT average_JJ calculated_VBN utilizing_VBG 2_CD
          to_TO 4_CD normal_JJ testes_NNS ._. The_DT effect_NN of_IN methylation_NN on_IN gene_NN
          expression_NN was_VBD similarly_RB assessed_VBN on_IN total_JJ RNA_NNP isolated_VBD
          from_IN cell_NN lines_NNS treated_VBN with_IN the_DT demethylating_VBG agent_NN
          5_CD -_: Aza-_NNP 2_CD '_POS deoxycytidine_NN (_( Sigma_NNP )_) for_IN five_CD days_NNS at_IN a_DT
          concentration_NN of_IN 2_CD -_: 5_CD μM_NN ._.
        
        
          Analysis_NNP of_IN mutations_NNS
          Single_NNP strand_NN conformational_NN polymorphism_NN (_( SSCP_NNP )_)
          analysis_NN was_VBD performed_VBN on_IN all_DT coding_VBG exons_NNS using_VBG primers_NNS
          flanking_VBG intronic_JJ sequences_NNS of_IN the_DT 
          MGMT_NNP gene_NN by_IN standard_JJ methods_NNS ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD (_( SK_NNP )_) carried_VBD out_RP the_DT MSP_NNP and_CC gene_NN expression_NN
        analysis_NN ._. Author_NN 2_CD (_( JH_NNP )_) coordinated_VBN the_DT selection_NN of_IN
        tumors_NNS ,_, and_CC isolation_NN of_IN genomic_JJ DNA_NNP and_CC RNA_NNP ._. Author_NN 3_CD (_( MM_NNP )_)
        participated_VBD in_IN the_DT analysis_NN of_IN gene_NN expression_NN ._. Authors_NNP 4_CD
        and_CC 5_CD (_( AD_NNP ,_, JMM_NNP )_) have_VBP collected_VBN the_DT clinical_JJ information_NN ._.
        Author_NN 6_CD (_( VER_NNP )_) participated_VBD in_IN histologic_JJ diagnosis_NN ._. Author_NN
        7_CD (_( GJB_NNP )_) was_VBD responsible_JJ for_IN referring_VBG the_DT patients_NNS and_CC
        clinical_JJ information_NN ._. Authors_NNP 8_CD and_CC 9_CD (_( RSKC_NNP and_CC VVVSM_NNP )_) have_VBP
        conceived_VBN and_CC coordinated_VBN the_DT study_NN ._. All_DT authors_NNS read_VBP and_CC
        approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
